Indian Biotechnology Industry Report

India Brand Equity Foundation (IBEF), established by Ministry of Commerce and Industry, published Indian Biotechnology Industry report.

Key Findings: India is among the top 12 biotechnology destinations in the world and third largest in Asia-Pacific.

• The industry was valued at $ 63 billion in 2019 and is expected to reach $ 150 billion by 2025.
• By 2025, the contribution of the Indian biotechnology industry in the global biotechnology market is expected to grow to 19% from 3% in 2017.
• The biotechnology sector is divided into five segments, which include biopharmaceuticals, bio-services, bio-agri, bio-industrial and bio-IT.
• In the Indian biotechnology market, Biopharmaceutical, which is the largest segment, accounted for ~62% in 2020 and ~58% in 2019.
• The biotechnology industry in India comprises >600 core biotech companies, >100 biotech incubators and ~4,000 biotech start-ups, which are estimated to reach 10,000 by 2024.
• India has 665 FDA-approved plants; 44% of the global abbreviated new drug applications (ANDA) and >1400 manufacturing plants, which are compliant with WHO.
• The country is also the world’s third-largest producer of recombinant Hepatitis B vaccine and second-largest producer of BT cotton (genetically modified pest resistant plant cotton).
• The Indian biologics market is expected to register a CAGR of 22% from 2019 to 2025 to reach US$ 12 billion by 2025.
• Bio-services, which accounted for 15% of the biotechnology industry in 2020, is becoming a leading destination for clinical trials, contract research and manufacturing activities in the country.
• India allows 100% FDI under the automatic route (a non-resident or Indian company will not require any approval from the government) for greenfield pharmaceuticals and manufacturing medical devices. Further 74% is permitted under automatic route for brownfield projects, 100% under government route is permitted for brownfield investments.